Gareth J. Morgan
Leeds Teaching Hospitals NHS Trust
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Gareth J. Morgan.
British Journal of Haematology | 2003
Robert A. Kyle; J. Anthony Child; Kenneth C. Anderson; Bart Barlogie; Régis Bataille; William Bensinger; Joan Bladé; Mario Boccadoro; William S. Dalton; Meletios A. Dimopoulos; Benjamin Djulbegovic; Mark Drayson; Brian G. M. Durie; Thiery Facon; Rafael Fonseca; Gösta Gahrton; Philip R. Greipp; Jean Luc Harousseau; David P. Harrington; Mohamad A. Hussein; Douglas E. Joshua; Heinz Ludwig; Gareth J. Morgan; Martin M. Oken; R. Powles; Paul G. Richardson; David Roodman; Jesús F. San Miguel; Kazuyuki Shimizu; Chaim Shustik
Summary. The monoclonal gammopathies are a group of disorders associated with monoclonal proliferation of plasma cells. The characterization of specific entities is an area of difficulty in clinical practice. The International Myeloma Working Group has reviewed the criteria for diagnosis and classification with the aim of producing simple, easily used definitions based on routinely available investigations. In monoclonal gammopathy of undetermined significance (MGUS) or monoclonal gammopathy, unattributed/unassociated (MG[u]), the monoclonal protein is <u200a30u2003g/l and the bone marrow clonal cells <u200a10% with no evidence of multiple myeloma, other B‐cell proliferative disorders or amyloidosis. In asymptomatic (smouldering) myeloma the M‐protein is ≥u200a30u2003g/l and/or bone marrow clonal cells ≥u200a10% but no related organ or tissue impairment (ROTI)(end‐organ damage), which is typically manifested by increased calcium, renal insufficiency, anaemia, or bone lesions (CRAB) attributed to the plasma cell proliferative process. Symptomatic myeloma requires evidence of ROTI. Non‐secretory myeloma is characterized by the absence of an M‐protein in the serum and urine, bone marrow plasmacytosis and ROTI. Solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomas (±u2003recurrent) are also defined as distinct entities. The use of these criteria will facilitate comparison of therapeutic trial data. Evaluation of currently available prognostic factors may allow better definition of prognosis in multiple myeloma.
Archive | 2001
Roger G. Owen; Sharon Barrans; Stephen J. Richards; J. Anthony Child; L. A. Parapia; Gareth J. Morgan; Andrew Jack
Archive | 2013
Philippa L. Roddam; R. A. Cartwright; Gareth J. Morgan; Martyn T. Smith; Yunxia Wang; Eleanor Kane; Sara Rollinson; Joseph L. Wiemels; Eve Roman
Archive | 2013
Stephen Mackinnon; Carmen Ruiz de Elvira; Catherine Williams; Stephen Devereux; David C. Linch; Stephen A. Schey; Premini Mahendra; Gareth J. Morgan; G Hale; Herman Waldmann; Stephen H. Robinson; Karl S. Peggs; Stephanie Verfuerth; Ruth Pettengell; D. Kottaridis; Donald Milligan; Rajesh Chopra; Ronjon Chakraverty
Archive | 2013
Sara Rollinson; Eve Roman; R. A. Cartwright; Gareth J. Morgan; Christine F. Skibola; Martyn T. Smith; Alan Hubbard; Barry Shane; Abby C. Roberts; Graham R. Law
Archive | 2013
Christopher McConkey; David Cunningham; Gareth J. Morgan; D. Catovsky; Donald Milligan; Savio Fernandes; Ranjit Dasgupta; Estella Matutes; Christopher D
Archive | 2010
Gareth J. Morgan; Carel J. M. van Noesel; Philip M. Kluin; James A. L. Fenton; Jan-Willem Vaandrager; Wilhelmina M. Aarts; Richard J. Bende; K. J. Heering
Archive | 2010
David Swirsky; Gareth J. Morgan; Christopher P. Wild; James M. Allan; Alex Smith; Keith Wheatley; Robert Kerrin Hills; Lois B. Travis; Deirdre A. Hill
Archive | 2005
Matthew W. Jenner; Brian A. Walker; Paola E. Leone; David Gonzalez; Fiona M. Ross; Cheng Li; Faith E. Davies; Gareth J. Morgan
Archive | 2004
Gareth J. Morgan; Faith E. Davies; Kim Hawkins; Sue E. Bell; Julia M. Nowlin Brown; Roger G. Owen